The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

von Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.
Veröffentlicht in Oncoimmunology (2019)

DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients

von Allera-Moreau, C, Rouquette, I, Lepage, B, Oumouhou, N, Walschaerts, M, Leconte, E, Schilling, V, Gordien, K, Brouchet, L, Delisle, M B, Mazieres, J, Hoffmann, J S, Pasero, P, Cazaux, C
Veröffentlicht 2012

Severe SARS-CoV-2 pneumonia: Clinical, functional and imaging outcomes at 4 months

von Noel-Savina, E., Viatgé, T., Faviez, G., Lepage, B., Mhanna, L.t, Pontier, S., Dupuis, M., Collot, S., Thomas, P., Idoate Lacasia, J., Crognier, L., Bouharaoua, S., Silva Sifontes, S., Mazieres, J., Prévot, G., Didier, A.
Veröffentlicht in Respir Med Res (2021)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

von Raynaud, C., Greillier, L., Mazieres, J., Monnet, I., Mastroianni, B., Robinet, G., Fraboulet, G., Dixmier, A., Berard, H., Lamy, R., Letreut, J., Lena, H., Oliviero, G., Botta, S., Vergnenegre, A., Borget, I., Chouaid, C.
Veröffentlicht in BMC Cancer (2015)

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

von Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Veröffentlicht in Ann Oncol (2018)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

von Girard, N., Greillier, L., Zalcman, G., Cadranel, J., Moro-Sibilot, D., Mazières, J., Audigier-Valette, C., Bennouna, J., Besse, B., Cortot, A., Couraud, S., Duruisseaux, M., Giroux-Leprieur, E., Toffart, A.-C., Westeel, V., Wislez, M.
Veröffentlicht in Respir Med Res (2020)

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)(†)

von Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., Kim, J.-H., Mazieres, J., Kim, S.-W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., Jänne, P. A.
Veröffentlicht in Ann Oncol (2015)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

von Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Veröffentlicht in Ann Oncol (2019)